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Abstract
Background: PYY is an appetite suppressing hormone. Low circulating PYY has been linked to greater BMI. However data is
controversial and this association has not been verified in large human populations.
Objective: The purpose of this study was to investigate if fasting serum total PYY is associated with obesity status and/or
adiposity at the population level.
Design: A total of 2094 subjects (Male-523, Female-1571) participated in this investigation. Total PYY was measured in
fasting serum by enzyme-linked immunosorbent assay. Obesity status (NW-normal-weight, OW-overweight and OB-obese)
was determined by the Bray Criteria according to body fat percentage measured by dual-energy x-ray absorptiometry and
the WHO criteria according to BMI. One-way ANOVA and multiple regression was used to assess the adiposity-specific
association between PYY and the following; weight, BMI, waist-circumference, hip-circumference, waist-hip ratio, percent
body fat (%BF), trunk fat (%TF), android fat (%AF) and gynoid fat (%GF).
Results: PYY was not significantly different among NW, OW and OB groups defined by neither %BF nor BMI for both men
and women. However among women, fasting PYY was positively associated with adiposity measures. Women with the
highest (Top 33%) waist-circumference, %BF and %TF had significantly higher PYY (10.5%, 8.3% and 9.2% respectively) than
women with the lowest (Bottom 33%). Age, smoking, medication use and menopause were all positively associated with
PYY levels in women but not in men.
Conclusion: To our knowledge this is the largest population based study, with the most comprehensive analysis and
measures of confounding factors, to explore the relationship of circulating PYY with obesity. Contrary to initial findings in
the literature we discovered that PYY was positively associated with body fat measures (waist-circumference, %BF and %TF)
in women. Although the effect size of the positive association of PYY with obesity in women is small, and potentially
negligible, it may in fact represent a protective response against significant weight gain.
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Introduction
Peptide YY (PYY), a 36 amino acid appetite suppressing gut
hormone, is secreted from the L-cells of the gastrointestinal tract.
Low levels of PYY have been reported to be associated with higher
BMI and obesity [1]. Circulating PYY increases satiety and
subsequently decreases food intake via gut-brain communication
[1,2,3], inhibits gastrointestinal motility [4] and pancreatic
hormone secretion [5,6]. In addition, it has been documented
that PYY plays an integral part in maintaining energy homeostasis
[7,8]. However, the involvement of PYY in the development of
human obesity is unclear [9,10,11], the relationship between
circulating PYY and adiposity is controversial [12], and very little
data exists from large human population-based studies.
Appetite, a key factor in energy homeostasis, significantly
influences the regulation of body weight [13]. Therefore investi-
gating appetite regulating hormones, such as PYY, may provide
valuable insight into the underlying mechanisms responsible for
the development of obesity. Initial PYY knockout studies revealed
that mice developed significant hyperphagia and that the acute
administration of PYY could significantly ameliorate this condition
[1,14,15]. This group also proposed that endogenous PYY
concentration was lower in obese rodents and humans, inversely
associated with obesity-related phenotypes [13], and the admin-
istration of PYY could effectively reduce food intake and body
weight independent of obesity status [1,13,14]. Therefore it was
hypothesized that a deficiency in circulating PYY could be a
significant contributing factor toward the chronic over consump-
tion of food and subsequent weight gain. However, many
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successive PYY knockout [16,17] studies have failed to reproduce
the strong association of PYY with hyperphegia and diet-induced
obesity. A considerable number of studies have also been unable to
replicate the original results in rodents or obese humans [11,18,19]
along with any significant association between circulating PYY
and adiposity [6,20,21].
Considering that very few cross-sectional studies with large
sample sizes have been performed considering confounding
variables and that the current results in the literature are
controversial; there is a necessity to explore the association of
circulating PYY with obesity at the population level. Therefore the
purpose of our study was to investigate the association of
circulating PYY concentration with obesity status and body
composition, measured by dual-energy x-ray absorptiometry, in a
large population adjusting for major confounding factors. The
detailed objectives were to: 1) test if PYY is associated with obesity
status by comparing fasting serum PYY between normal-weight
(NW), overweight (OW) and obese (OB) men and women; 2)
examine the association of PYY with body composition among
normal-weight (NW), overweight (OW) and obese (OB) men and
women; and 3) determine the influence of age, sex, smoking,
medication use and menopausal status on circulating PYY.
Methods
Ethics Statement
This study was approved by The Health Research Ethics
Authority (HREA) for the Faculty of Medicine, Memorial
University of Newfoundland and Labrador, St John’s, Canada.
All subjects provided written informed consent.
Subjects
A total of 2094 subjects from the Complex Diseases in the
Newfoundland population: Environment and Genetics (COD-
ING) study (Male 523, Female 1571) was used for this
investigation [22,23,24,25,26]. All participants of this current
study were from the Canadian province of Newfoundland and
Labrador. Eligibility of participants for the CODING study was
based upon the following inclusion criteria: 1).19 yrs of age; 2) at
least a third generation Newfoundlander; and 3) healthy, without
any serious metabolic, cardiovascular, or endocrine diseases. The
primary method of subject recruitment for the CODING study
was the use of posters and handouts. This literature was distributed
throughout public facilities (offices, and hospitals) in the city of St.
John’s, Newfoundland and Labrador. Each individual completed a
number of questionnaires to obtain information regarding lifestyle
and physical activity. Anthropometric, body composition and
biochemical measurements were performed following a 12-h
fasting period.
Anthropometric and Body Composition Measurements
Height (cm) and weight (nearest 0.1 kg) measurements were
collected and Body Mass Index (BMI) calculated. BMI was defined
as weight divided by height squared (kg/m2). Waist circumference
(cm) was measured as the horizontal distance around the abdomen
at the level of the umbilicus, and hip circumference (cm) was
measured as the largest circumference between the waist and
thighs. Height, waist and hip measurements were recorded to the
nearest 0.1 cm. Percent body fat (%BF), percent trunk fat (%TF),
percent android (abdominal) fat (%AF) and percent gynoid (lower
abdominal-thigh) fat (%GF) were measured, in a supine position,
utilizing dual-energy X-ray absorptiometry (DXA, Lunar Prodigy;
GE Medical Systems, Madison, WI). The Lunar Prodigy software
system determines automatically the regions for the assessment of
%TF, %AF, %GF. %TF region is from the top of the shoulders to
the top of the iliac crest, while the %AF region is the top of the
second lumbar vertebra to the top of the iliac crest and the %GF
region extends down iliac crest twice the height of the android
area. The current version of the enCORE software for the DXA
data presented within this manuscript cannot differentiate visceral
from subcutaneous fat. Therefore the %TF, %AF, and %GF
regions represent the summation of both subcutaneous and
visceral fat relative to these regions. DXA produces an accurate
measurement of adipose tissue within the body with a low margin
of error. For this reason, DXA is considered to be one of the most
reliable measurements of adiposity and is commonly used as a
standard compared to less accurate field methods such as BMI.
The enCORE (Ver 12.2, 2008, GE Medical Systems, Madison,
WI) software package was used for DXA data acquisition. Quality
assurance was performed on the DXA scanner daily and the
typical CV during the study period was 1.4%.
Total PYY Measurement
Fasting blood samples were obtained and serum was stored at2
80uC for subsequent analyses. Serum total PYY concentration was
determined via an enzyme-linked immunosorbent assay (Millipore
Corporation Pharmaceuticals, Billerica, MA, USA). Due to the
large number of participants in this current investigation samples
were measured in singlet. However the intraassay (range of 4.8%
to 5.4%) and interassay (5.1%) variation from our previous study,
[20] and the measurements of PYY in the current study, were
performed by the same research assistant. The detection limit of
the PYY enzyme-linked immunosorbent assay used was 10 pg/mL
for a sample size of 20 mL.
Lifestyle Assessment
All participants completed a self-administered screening ques-
tionnaire, which queried covariates including smoking (smoker,
non-smoker) and medication (medication user, non-medication
user). Female subjects were screened for menopausal status (Pre-
menopause, Post-menopause) by questionnaire.
Data Analysis
Data are presented as means 6 standard deviation (SD) unless
otherwise stated. Participants with PYY concentrations falling
outside the range of 63 SDs (n = 27) were considered outliers and
excluded from analyses. The influence(s) of sex (Men vs. Women)
environmental factors (smoking vs non-smoking, medication vs
non-mediation user) and menopause (pre-menopause vs post-
menopause) on PYY concentration were assessed using indepen-
dent sample t-tests. Pearson correlation analysis was also
performed to assess the association of circulating whole PYY with
body composition measurements for the entire cohort along with
males and females separately. Obesity status (normal-weight,
overweight, and obese) for participants (n = 2094) was determined
based on %BF according to the, age and sex specific, criteria
recommended by Bray [27]. Obesity status was also grouped
based on BMI as normal-weight (NW; 18.5–24.9 kg/m2), over-
weight (OW; 25.0–29.9 kg/m2) or obese (OB; $30 kg/m2)
according to criteria of the World Health Organization [28]. To
further explore the association of PYY with body composition we
stratified subjects into tertiles according to waist circumference,
hip circumference, waist-hip ratio, BMI, %BF, %TF, %AF and
%GF. Participants were also divided into tertiles according to
fasting serum PYY concentrations (pg/ml) to examine differences
in adiposity measurements. Subsequently, adjusted and unadjusted
multiple regression analyses were used to further explore the
associations found between body composition measurements and
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circulating PYY concentration. The effect of age on the
relationship between PYY and adiposity was also thoroughly
explored. PYY concentrations were compared among normal-
weight, overweight, and obese participants, defined by %BF
according to the Bray Criteria, from four different age groups: 1)
younger than 30 years of age (,30 yrs); 2) 30years of age and
greater but less than 40 years of age ($30 yrs–,40 yrs); 3) 40
years of age and greater but less than 50 years of age ($40 yrs–,
50 yrs); and 4) 50 years of age and greater ($50 yrs).
Differences in PYY concentration among obesity statuses (NW,
OW, OB), body composition tertiles (low, medium, high), were
analyzed by one-way analysis of covariance (One-way ANCOVA)
controlling for age, sex, smoking, medication use, and menopause.
Multiple regression analysis also included age, sex, smoking,
medication use, and menopausal status as potential covariates. R
statistical software package version 2.15.2 (R development core
team) was used for all analyses. Statistical analyses were two-sided
and a P value,0.05 was considered to be statistically significant.
Table 2. Pearson correlation of body composition measurements with circulating PYY1,2.
Entire Cohort Male Female
(n=2094) (n =523) (n =1571)
r p r p r p
Age (y) 0.05 0.031 0.03 NS 0.07 0.009
Weight (kg) 0.05 0.027 20.03 NS 0.04 NS
Height (cm) 0.05 0.017 0.02 NS 0.01 NS
BMI (kg/m2) 0.03 NS 20.03 NS 0.04 NS
Waist (cm) 0.06 0.003 20.01 NS 0.07 0.003
Hip (cm) 0.04 NS 20.04 NS 0.07 0.007
Waist-Hip Ratio 0.06 0.008 0.03 NS 0.03 NS
Body fat (%) 20.01 NS 20.02 NS 0.05 0.043
Trunk fat (%) 0.01 NS 20.01 NS 0.06 0.025
Android fat (%) 0.01 NS 0.00 NS 0.05 0.056
Gynoid fat (%) 20.05 NS 20.03 NS 0.01 NS
1Pearson correlation of body composition measurements with PYY (pg/ml).
2Statistical significance was set to p,0.05.
doi:10.1371/journal.pone.0095235.t002
Figure 1. Fasting serum PYY among normal-weight, overweight and obese males and females. Fasting PYY concentration was not
significantly different between normal-weight (NW), overweight (OW) or obese (OB) subjects defined either by body mass index (BMI) according to
the WHO criteria [28] or percent body fat (%BF) measured by dual-energy x-ray absorptiometry (DXA) according to the Bray criteria [27]. Fasting PYY
concentration was also not significantly different among adiposity groups among men and women separately.
doi:10.1371/journal.pone.0095235.g001
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Results
PYY Concentration and Body Composition
Measurements among Male and Female Participants
Body composition characteristics and PYY concentration
from both male and female subjects are shown in Table 1.
Independent t-test analysis revealed that PYY, weight, height,
BMI, waist circumference and waist-hip ratio were significant-
ly greater for men than women. Women were significantly
greater than men for age, hip circumference, %BF, %TF,
%AF, and %GF. Sex differences for body composition
measurements among Newfoundland and Labradoreans have
been previously described by us [24,25,26]. Fasting serum total
PYY concentrations were found to be approximately 9%, or
11 pg/ml, higher in men than in women (Table 1).
Association of Lifestyle/Environmental Factors with PYY
Concentration
The influence of lifestyle and environmental factors such as
smoking, medication use, and menopause on circulating PYY
concentration were explored. None of these factors had an
influence on PYY concentration for men. Female smokers had
a 9.7% higher fasting PYY concentration than female non-
smokers (120.50677.6 pg/ml vs 109.87673.5 pg/ml, p,
0.04). PYY concentration was significantly higher for female
medication users (114.51675.5 pg/ml) over non-medications
users (106.71672.4 pg/ml) (p = 0.04). With regards to meno-
pausal status, PYY concentration was 10.3% greater for post-
menopausal women over pre-menopausal women
(117.78678.3 pg/ml vs 106.70671.5 pg/ml, p,0.006). Age,
weight, BMI, waist circumference, hip circumference, %BF,
%TF, %AF and %GF were all significantly greater for post-
menopausal women compared to pre-menopausal women (p,
0.004). Lastly, to investigate the potential compound effect of
smoking, medication use, and menopausal status on fasting
PYY concentration for women we compared post-menopause
smoking medication users (n = 53) with pre-menopause non-
smoking non-medication users (n = 376). The post-menopause
smoking medication users group (139.40693.7 pg/ml) had a
38.6% higher fasting PYY concentration than pre-menopause
non-smoking non-medication users (100.60667.7)(p,0.005)
independent of age, BMI and %BF.
Pearson Correlation Analysis of Body Composition
Measurements with Circulating PYY
Pearson correlation analysis of weight, height, BMI, waist
circumference, Hip circumference, waist-to-hip ratio, %BF, %TF,
%AF, %GF with circulating PYY are shown in Table 2.
Although no association was found between any of the body
composition measurements with PYY (pg/ml) in men, age (y),
weight (kg), height (cm), waist circumference (cm) and the waist-to-
hip ratio were significantly positively associated with circulating
PYY (pg/ml) in the entire cohort. Additionally, age, waist
circumference, hip circumference, %BF, and %TF were signifi-
cantly positively associated with circulating PYY (pg/ml) in
women.
PYY Concentration and Body Composition among
Normal-weight, Overweight and Obese for Male and
Females Participants
Body composition characteristics and PYY for NW, OW and
OB men and women are shown in Table 3. Fasting total PYY
concentration was not significantly different among NW, OW,
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and OB subjects within the entire cohort or for either sex
(Table 3). Weight, BMI, waist circumference, hip circumfer-
ence, waist-hip ratio, %BF, %TF, %AF and %GF all
significantly increased with the concomitant increase in
adiposity status within the entire cohort and for both sexes.
There was also no significant difference in circulating PYY
when these adiposity groups were classified by BMI according
to the WHO criteria (Figure 1).
PYY Concentration and Body Composition
Measurements among Tertiles (Low, Medium, and High)
According to Body Composition Measurements and PYY
Concentration
To further explore the potential relationship between PYY and
body composition, PYY concentrations were compared among
subjects stratified into tertiles according to obesity-related pheno-
types (waist circumference, hip circumference, BMI, %BF, %TF,
%AF and %GF). We found no significant difference in PYY
Table 6. Multiple Regression for Body Fat (%), Trunk Fat (%), and Waist Circumference (cm) on PYY Concentration1,3.
Unadjusted2 Adjusted2
b p b p
Body Fat (%)
Entire Cohort 20.1083 (0.183) NS 20.2984 (0.195) NS
Male 20.1984 (0.451) NS 20.1368 (0.476) NS
Female 0.5417 (0.267) 0.043 0.2786 (0.285) NS
Trunk Fat (%)
Entire Cohort 0.056 (0.179) NS 20.1105 (0.194) NS
Male 20.1312 (0.386) NS 20.1424 (0.421) NS
Female 0.5170 (0.230) 0.025 0.3090 (0.247) 0.045
Waist Circumference
Entire Cohort 0.3414 (0.1154) 0.003 0.2982 (0.1208) 0.02
Male 20.0720 (0.253) NS 20.0943 (0.2692) NS
Female 0.3930 (0.133) 0.003 0.2826 (0.1437) 0.049
1Regression model adjusted for age, gender, smoking, medication use (Menopause was also controlled for in the females).
2b=Unstandardized Beta (standard error).
3Statistical significance was set to p,0.05.
doi:10.1371/journal.pone.0095235.t006
Figure 2. Fasting Serum PYY for men and women in four age groups. Fasting PYY concentration was 15.2%, 17.1% and 11.8% greater among
men than women within the ,30 yrs, .30–,40 yrs, and .40–,50 yrs groups respectively (*). Additionally, the $50 yrs group of women had a
12.2% higher circulating level of PYY than women in the ,30 yrs group ({).
doi:10.1371/journal.pone.0095235.g002
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concentration among any of the body composition measurement
tertiles, or a difference in any of the body composition values
among the PYY tertiles, in men (Table 4&5). However, PYY
concentrations were significantly associated with the increase in
waist circumference, %BF, and %TF and these same body
composition measurements were significantly associated with the
concomitant increase of PYY concentration in women
(Table 4&5). PYY concentration was also significantly associated
with the increase in waist circumference and waist-hip ratio before
and after adjustment for the entire cohort. Hip circumference and
waist-hip ratio are also positively associated with the increase in
circulating PYY before and after adjustment for the entire cohort
and women (Table 4&5). Lastly, %AF was significantly
associated with the increase in circulating PYY concentration in
females (Table 4&5).
Multiple Regression Analysis of Body Composition
Measurements with Circulating PYY
Unadjusted and adjusted linear regression analysis results of
%TF, %BF, and waist circumference on circulating PYY are
shown in Table 6. No association was found between %TF (%) or
%BF (%) with PYY (pg/ml) in the entire cohort or among men.
Although waist circumference (cm) was not associated with
circulating PYY in men, it was positively correlated with the
entire cohort before and after the adjustment for age, smoking,
medication use and menopausal status. Circulating PYY was
positively associated with waist circumference (cm), %TF (%), and
%BF (%) in women before adjustment for confounding factors.
However after the adjustment for age, smoking, medication use
and menopausal status only %TF (%) and waist circumference
(cm) remained significantly associated with PYY in women
(Table 6).
Association of Age with Circulating PYY Concentration
Circulating PYY were also analyzed among normal weight,
overweight and obese men and women for 4 different age ranges
(,30 yrs, $30 yrs–,40 yrs, $40–,50 yrs, and $50 yrs). No sex
differences for PYY concentration were found among normal-
weight, overweight and obese for any of the 4 age groups (Data no
shown) and circulating total PYY concentration was not signifi-
cantly different among adiposity groups within any of the 4 age
ranges (Data no shown). However, PYY concentration was 15.2%,
17.1% and 11.8% greater among men than women within the ,
30 yrs, .30–,40 yrs, and .40–,50 yrs groups respectively
(Figure 2.). Additionally, the $50 yrs group from women had
12.2% higher circulating PYY than women in the ,30 yrs group
(118.1677.1 vs 105.3663.9) (Figure 2).
Discussion
One major finding for the present study is that serum PYY is
not negatively associated with obesity status defined by BMI or
%BF adjusting for age, sex, smoking, medication use, and
menopause. Contrary to the current literature we have demon-
strated for the first time that fasting serum PYY is positively
associated with %BF, %TF, and waist circumference in women.
Additionally, circulating PYY was greater among men compared
to women, and is affected by age, smoking, medication use and
menopausal status in women only.
PYY is an anorexigenic peptide, released from the L-cells of the
lower intestine, which acts centrally within the hypothalamus to
inhibit the orexigenic activity of the neuropeptide Y (NPY)
[13,29]. The initial investigations involving PYY, conducted in
rodents, revealed that a diet-induced obesity state decreased PYY
concentrations. Suggesting that the circulating concentration of
this appetite suppressing gut hormone is associated with the
development of obesity [15,30]. Studies conducted on a small
sample of humans showed that endogenous PYY concentrations
were lower in obese subjects and inversely correlated with obesity-
related phenotypes [13,15,31,32]. However, other rodent [11] and
human based [18,20,21,33] studies have failed to reproduce the
strong inverse relationship between circulating PYY and adiposity.
Additionally, an extensive review in 2005, exploring the anorex-
igenic effect of PYY, revealed 84% studies produced among 41
independent research groups were unable to reaffirm the claim
proposed by the initial investigations [12]. Data from human
studies are limited, inconsistent, contain small sample sizes and
have utilized less accurate obesity measures (like BMI) in place of
more accurate measures of body fat. Moreover, our laboratory
and others have shown that BMI cannot accurately distinguish fat
mass from fat-free mass and is not an accurate predictor of
adiposity [24,26]. Therefore the inaccurate measurement of
adiposity and the misclassifications of obesity status could be the
factor attributing to the contradictory reports concerning the
association of PYY with obesity. The first important finding from
the present study is that circulating PYY was not significantly
different among normal-weight, overweight and obese participants
and these findings were consistent whether obesity status was
defined either by %BF or BMI. Additionally, a recent study by our
laboratory was also unable to detect an association of circulating
PYY with obesity status (defined either by BMI or %BF) in a
cohort consisting of young men [20]. Considering the power of the
present study, with over 2000 subjects, our results indicate that
circulating PYY concentration is not likely a significant factor
affecting obesity status at the population level. However, after
extensive analysis we have shown that circulating PYY is positively
associated with obesity measures related to body fat in women.
PYY concentration was 10.5%, 8.3%, and 9.2% greater among
women with the highest waist circumference, %BF and %TF,
respectively, compared to women with the lowest aforementioned
body fat measures. This finding was also supported by the fact that
waist circumference, %BF and %TF were greatest among women
with the highest tertile according to PYY concentration and that
unadjusted multiple regression analysis revealed a significant
positive influence of waist circumference, %BF and %TF. The
positive relationship found in our study between PYY and body fat
measures are in direct opposition to the negative association
theory. However, among the results of a study [34] designed to
investigate various metabolites in insulin resistance, we discovered
that PYY concentration was greater among obese subjects
compared to normal-weight subjects. Although the primary
objective of this study was not investigating PYY and obesity
status, their results are consistent with our current findings. The
increased level of PYY in circulation is likely a protective response
of human body to the obese state. Nevertheless, more studies are
needed to verify our findings in other populations.
The potential influence(s) of sex, age, smoking, medication use
and menopause on fasting serum PYY concentration were also
examined. Studies have reported gender differences in circulating
PYY levels. One study found that PYY was higher in men
compared to women [35], while others found that PYY levels are
higher in women [21]. In the present study we discovered that
fasting serum PYY was 9% higher in men compared to women.
Findings from our current study, along with those of others,
suggest that circulating PYY concentration is not significantly
affected by age [21,32,35]. However, when evaluating the
influence of age on PYY among females, a positive association
was found. Smoking and medication use did not affect PYY
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concentration in men, but these factors did significantly increase
circulating PYY levels in women. Circulating PYY concentration
was 9.7 and 7.3% greater among female smokers and medication
users over non-smoker and non-medication users respectively.
Currently, there is very little evidence to suggest that smoking and
medication use affect circulating PYY. However some data, from
animal models, does propose that nicotine [36,37,38] and various
medications [39,40,41] can increase circulating PYY. Specifically,
rodent studies have shown that nicotine can significantly increase
mRNA expression and the production of PYY protein [36] along
with the significant attenuation of neuropeptide Y (NPY) mRNA
expression and production of NPY protein [37,38]. Therefore, it is
probable that the inhibition of appetite, due to smoking, could be
partially attributed to the stimulation of PYY and the inhibition of
NPY in women. Lastly, post-menopausal women had significantly
greater PYY than pre-menopausal women. However, since more
than 70% of our post-menopausal women are medication users
and that menopause is strongly associated with age, the up
regulation of PYY could be an age and drug related interference.
Therefore we investigated the potential compound effect of
smoking, medication use, and menopausal status on fasting PYY
concentration for women. The analysis revealed that post-
menopause, smoking, medication users had a 38.6% higher
fasting PYY concentration than pre-menopause, non-smoking,
non-medication users. This compound effect was unchanged after
controlling for age, BMI and %BF. Our study provides strong
evidence that there is an obvious sex difference regarding fasting
PYY concentration and that age, smoking, medication use and
menopausal status all significantly influence circulating PYY
concentration in women and not men.
The primary limitation of the present study is that we only
investigated total PYY rather than PYY3–36 alone which has been
suggested to be the more significantly active form of PYY.
However, total levels of PYY are well correlated with PYY3–36 [15]
and both PYY3–36 and PYY1–36 have been found to decrease
gastrointestinal motility [6]. Secondly, due to a significant number
of subjects in the current study, singlet measurements of PYY were
collected from a single serum sample for each subject. However,
due to the fact that the intraassay (range of 4.8% to 5.4%) and
interassay (5.1%) variation from our previous study [20] were low,
and that the measurement of PYY in the current study was
performed by the same research assistant, we are confident that
our data is accurate. Moreover, the large sample size further
strengthens the reliability. Thirdly, although our findings strongly
suggest that PYY is not a significant player in determining obesity
status, it must be acknowledged that our samples were collected in
a fasted state. Population studies, monitoring the dynamic
postprandial response of PYY concentration to various standard-
ized diets, should be performed.
In summary, the association of fasting serum PYY concentra-
tion with obesity status and body fat measures was investigated
among 2094 adults from the Canadian province of Newfoundland
and Labrador. To the best of our knowledge this is the largest
cross-sectional study to systematically evaluate the relationship
between peripheral circulating PYY concentrations with adiposity.
Our results indicate that PYY is not significantly associated with
obesity status defined by either %BF or BMI. However, circulating
PYY is influenced by age, smoking, medication use, and
menopausal status in women. Moreover contradictory to previous
studies, fasting serum PYY in the present study was significantly
associated with waist circumference, %BF, and %TF in women.
Although the effect size of the positive association of PYY with
adiposity in women is small, and potentially negligible, it may in
fact represent a protective response to extreme weight gain.
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